Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Shaffer

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancerDavid R Shaffer, Margaret A Leversha, Daniel C Danila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyDaniel P Petrylak, Yohann Loriot, David R Shaffer, et al.
Nature Genetics|June 4, 2013
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasionGuocan Wang, Andrea Lunardi, Jiangwen Zhang, et al.
Journal for Immunotherapy of Cancer|August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialKarim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancerDavid R Shaffer, Margaret A Leversha, Daniel C Danila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyDaniel P Petrylak, Yohann Loriot, David R Shaffer, et al.
Nature Genetics|June 4, 2013
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasionGuocan Wang, Andrea Lunardi, Jiangwen Zhang, et al.
Journal for Immunotherapy of Cancer|August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialKarim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Pageof 2